Table 1.

Demographics and baseline clinical characteristics

	Sonidegib 200 mg (n = 79)	Vismodegib 150 mg (n = 119)	P value
Age, years, median (range)	67.0 (25–92)	62.0 (24–100)	N/A
Sex, male	48 (60.8)	88 (73.9)	0.0607*
ECOG performance status
0	50 (63.3)	69 (58.0)	0.1515†
1	19 (24.1)	41 (34.5)
2	8 (10.1)	9 (7.6)
Unknown	2 (2.5)	0
Stage
laBCC	66 (83.5)	62 (52.1)	< 0.0001*
mBCC	13 (16.5)	57 (47.9)

BCC basal cell carcinoma, ECOG Eastern Cooperative Oncology Group, laBCC locally advanced BCC, mBCC metastatic BCC, N/A not available

Data presented as n (%) of patients unless otherwise indicated

*Two-sided Fisher’s exact test

^†χ² test, two-sided